17 Nov, 2021
\n \n \n \nThe Chan Zuckerberg Initiative (CZI) has provided $2 million in funding to investigate how our ancestry and diversity influence the way that vaccines work in our cells.
\n \n\n \n \n5 Nov, 2021
\n \n \n \nAn international study of more than 50,000 people with irritable bowel syndrome (IBS) has revealed that IBS symptoms may be caused by the same biological processes as conditions such as anxiety. The research highlights the close relationship between brain and gut health and paves the way for development of new treatments.
\n \n\n \n \n22 Oct, 2021
\n \n \n \nMillions of patients with ulcerative colitis or Crohn\u2019s disease, collectively known as inflammatory bowel disease (IBD), are given fresh hope as a new study shows why some of them do not respond to current treatments.
\n \n\n \n \n15 Oct, 2021
\n \n \n \nA new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.
\n \n\n \n \n6 Oct, 2021
\n \n \n \nInhye Park has been awarded a Novo Nordisk Postdoctoral Research Fellowship to research the biology of resident vascular macrophages in atherosclerosis.
\n \n\n \n \n29 Sep, 2021
\n \n \n \nTonia Vincent, Jelena Bezbradica and Alex Clarke have been awarded funding grants by the Medical Research Council (MRC) for different projects.
\n \n\n \n \n17 Sep, 2021
\n \n \n \nThe Medical Sciences Division has awarded the title of Associate Professor to five senior researchers at NDORMS.
\n \n\n \n \n17 Aug, 2021
\n \n \n \nBuilding work at the Kennedy Institute of Rheumatology has finished, providing a new third floor that houses additional meeting and collaboration space for data science and offices for the management of clinical trials.
\n \n\n \n \n16 Aug, 2021
\n \n \n \nJethro Johnson, Deputy Director of the Oxford Centre for Microbiome Research explains how the centre is building a research community to understand the microbiome and harness its power to promote health and prevent disease.
\n \n\n \n \n6 Aug, 2021
\n \n \n \nAs part of the University of Oxford\u2019s mission to provide its researchers with the newest state-of-the-art optical imaging equipment and as part of a strategic partnership with the Kennedy Institute of Rheumatology (KIR), the Institute of Developmental and Regenerative Medicine (IDRM), and Carl Zeiss AG (ZEISS), ZEISS has installed a ZEISS Lattice Lightsheet 7 microscope at the KIR.
\n \n\n \n \n26 Jul, 2021
\n \n \n \nResearchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.
\n \n\n \n \n15 Jul, 2021
\n \n \n \nNew research shows that disrupting primary cilia in juvenile, adolescent and early adulthood in cartilage stops it maturing correctly, making it more prone to thinning and the potential for osteoarthritis (OA) in later life.
\n \n\n \n \n25 Jun, 2021
\n \n \n \nA new study published in The Lancet Rheumatology shows potential ways to predict how likely someone is to develop osteoarthritis after a knee injury.
\n \n\n \n \n21 Jun, 2021
\n \n \n \nPostdoctoral Researcher Ghada Alsaleh has been awarded a research grant by Versus Arthritis which she will use to develop a new therapy for osteoarthritis.
\n \n\n \n \n10 Jun, 2021
\n \n \n \nA new study published in Circulation Research shows that CD200, an inhibitory immune checkpoint, reduces the development of atherosclerosis.
\n \n\n \n \n7 Jun, 2021
\n \n \n \nResearchers at the Kennedy Institute join a collaboration to find new \u2018drug-free\u2019 ways of treating illnesses where current treatments have become ineffective due to antibiotic resistance.
\n \n\n \n \n20 May, 2021
\n \n \n \nResearchers at the Kennedy Institute demonstrate that the drug decitabine can boost regulatory T cell responses.
\n \n\n \n \n17 May, 2021
\n \n \n \nProfessor Anjali Kusumbe and Professor Cyrus Cooper have been presented with research awards by the European Calcified Tissue Society (ECTS).
\n \n\n \n \n12 May, 2021
\n \n \n \nProfessor of Immunology Katja Simon has been elected as a Fellow of the Academy of Medical Sciences.
\n \n\n \n \n4 May, 2021
\n \n \n \nProfessor Michael Dustin and an international team of collaborators have been awarded a \u20ac10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.
\n \n\n \n \n